ライフサイエンスコーパス: inflammatory polyarthritis

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 polyarthritis compared with patients without inflammatory polyarthritis.

2 rge primary care-based register of new-onset inflammatory polyarthritis.

3 5% CI 1.1-7.5) were at an increased risk for inflammatory polyarthritis.

4 ng the first 5 years after presentation with inflammatory polyarthritis.

5 f patients who present with undifferentiated inflammatory polyarthritis.

6 of overall cancer survival in patients with inflammatory polyarthritis.

7 f mice is an animal model of T cell-mediated inflammatory polyarthritis.

8 s reduced in patients following the onset of inflammatory polyarthritis.

9 ses of cancer in the cohort of patients with inflammatory polyarthritis.

10 , and tumor type, mortality in patients with inflammatory polyarthritis and cancer was significantly

11 association (OR 1.8, 95% CI 1.4-2.4) between inflammatory polyarthritis and the presence of any share

12 ter, a primary care-based inception study of inflammatory polyarthritis, and were matched for age and

13 cancer survival was reduced in patients with inflammatory polyarthritis compared with patients withou

14 We recruited 532 patients with inflammatory polyarthritis from the Norfolk Arthritis Re

15 higher all-cause mortality in patients with inflammatory polyarthritis (hazard ratio, 1.16 [95% CI,

16 utcome in unselected patients with new-onset inflammatory polyarthritis (IP) has not been examined.

17 certainment of RA in subjects with new-onset inflammatory polyarthritis (IP) over the first 5 years o

18 functional outcome and OC use in women with inflammatory polyarthritis (IP).

19 3 years among patients newly presenting with inflammatory polyarthritis (IP).

20 functional disability in patients with early inflammatory polyarthritis (IP).

21 nvolving adult patients, ages 18-70, with an inflammatory polyarthritis of <12 months' duration who w

22 A cohort of 680 consecutive patients with inflammatory polyarthritis, of whom 404 satisfied the Am

23 n C are associated with an increased risk of inflammatory polyarthritis or rheumatoid arthritis.

24 ster (NOAR) of all patients who had onset of inflammatory polyarthritis (swelling of > or =2 joints)

25 100 mg orally twice daily) was a symptomatic inflammatory polyarthritis that persisted for up to 8 we

26 heumatoid arthritis (RA) causes a symmetric, inflammatory polyarthritis that results in joint destruc

27 The risk for development of inflammatory polyarthritis was compared between subjects

28 of cancer among this cohort of patients with inflammatory polyarthritis was not increased compared wi

29 rom 439 subjects who sought primary care for inflammatory polyarthritis were analyzed.

30 Between 1993 and 2002, 88 new patients with inflammatory polyarthritis were identified and matched w

31 Patients with new cases of inflammatory polyarthritis were identified by linkage wi

32 The dose-limiting toxicity (DLT) was severe inflammatory polyarthritis, which seemed to be a cumulat

33 Rheumatoid arthritis is a chronic inflammatory polyarthritis whose etiology remains uncert

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。